Racial Variation in ACE--Genetic and Physiologic Bases

NCT00005757 | Completed

• 2 other identifiers: 5115R29HL056963
• Study Type: observational
• Target: 293
• Locations: 0 countries
• Sites: N/A

Brief Summary

To determine whether differences in the activity of the renin-angiotensin and bradykinin systems are involved in the pathogenesis of blood pressure variation in African Americans.

Conditions

Cardiovascular Diseases; Heart Diseases; Hypertension

Eligibility Criteria

• Age: Up to 100 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

No eligibility criteria

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Vanderbilt University: lead
• National Heart, Lung, and Blood Institute (NHLBI): collaborator

Related Publications (9)

• Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension. 1998 Dec;32(6):965-71. doi: 10.1161/01.hyp.32.6.965.

  PMID: 9856958 BACKGROUND

• Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998 Oct 29;339(18):1285-92. doi: 10.1056/NEJM199810293391804.

  PMID: 9791144 BACKGROUND

• Murphey LJ, Hachey DL, Vaughan DE, Brown NJ, Morrow JD. Quantification of BK1-5, the stable bradykinin plasma metabolite in humans, by a highly accurate liquid-chromatographic tandem mass spectrometric assay. Anal Biochem. 2001 May 1;292(1):87-93. doi: 10.1006/abio.2001.5073.

  PMID: 11319821 BACKGROUND

• Gainer JV, Brown NJ, Bachvarova M, Bastien L, Maltais I, Marceau F, Bachvarov DR. Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans. Am J Hypertens. 2000 Dec;13(12):1268-73. doi: 10.1016/s0895-7061(00)01215-2.

  PMID: 11130770 BACKGROUND

• Murphey LJ, Kumar S, Brown NJ. Endogenous bradykinin and the renin and pressor responses to furosemide in humans. J Pharmacol Exp Ther. 2000 Nov;295(2):644-8.

  PMID: 11046100 BACKGROUND

• Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 2000 Sep;58(3):1219-27. doi: 10.1046/j.1523-1755.2000.00277.x.

  PMID: 10972684 BACKGROUND

• Murphey LJ, Gainer JV, Vaughan DE, Brown NJ. Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation. 2000 Aug 22;102(8):829-32. doi: 10.1161/01.cir.102.8.829.

  PMID: 10952948 BACKGROUND

• Murphey LJ, Hachey DL, Oates JA, Morrow JD, Brown NJ. Metabolism of bradykinin In vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite. J Pharmacol Exp Ther. 2000 Jul;294(1):263-9.

  PMID: 10871321 BACKGROUND

• Wilsdorf T, Gainer JV, Murphey LJ, Vaughan DE, Brown NJ. Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm. Hypertension. 2001 Apr;37(4):1136-40. doi: 10.1161/01.hyp.37.4.1136.

  PMID: 11304515 BACKGROUND

MeSH Terms

Conditions

Cardiovascular Diseases; Heart Diseases; Hypertension

Condition Hierarchy (Ancestors)

Vascular Diseases

Study Officials

• Nancy Brown

  Vanderbilt University

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: May 25, 2000
• First Posted: May 26, 2000
• Study Start: September 1, 1997
• Primary Completion: August 1, 2001
• Study Completion: August 1, 2001
• Last Updated: November 28, 2016

Record last verified: 2016-11